Intellia Therapeutics

NTLA · NASDAQ

$11.84+$0.26 (+2.25%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $11.58

NTLA analyst rating

HoldConsensus of 21 analysts over the last 12 months. 52% rate it a buy.

Strong buy0
Buy11
Hold6
Underperform3
Sell1

12-month price target · 18 analysts

Average $25.36 (+114.2% upside)

Low: $9.09
Now: $11.84
High: $64.05

Upgrades and downgrades

The latest rating actions, newest first

NTLA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 6, 2026	Initiates	Underweight	$8.00	45%
Citizens	Sep 9, 2026	Maintains	Market Outperform	$30.00	14%
Wedbush	Sep 9, 2026	Maintains	Neutral	$12.00 → $13.00	46%
HC Wainwright & Co.	Sep 9, 2026	Maintains	Buy	$25.00	32%
Citizens	Aug 25, 2026	Maintains	Market Outperform	$30.00	14%
Evercore ISI Group	Aug 7, 2026	Upgrade	In-Line → Outperform	$16.00 → $24.00	9%
Wolfe Research	Jul 16, 2026	Downgrade	Peer Perform → Underperform	$9.00	47%
Wedbush	Jul 10, 2026	Maintains	Neutral	$12.00 → $17.00	46%
Canaccord Genuity	Jun 16, 2026	Maintains	Buy	$49.00	41%
Citizens	Jun 15, 2026	Maintains	Market Outperform	$30.00	14%

The case for and against

Updated Oct 14, 2026

Bull case

Intellia Therapeutics is viewed favorably because its lead HAE program, lonvo-z, has already shown compelling clinical differentiation, with an 87% reduction in mean monthly attacks versus placebo and 62% of patients remaining attack free over the six-month evaluation period. The FDA’s acceptance of the BLA with Priority Review, a March 10, 2027 PDUFA date, and no planned AdCom materially de-risk the path to approval, shifting attention from efficacy to final benefit-risk, CMC, and inspection issues. A potential approval would not only create the first U.S. regulatory precedent for systemic in vivo CRISPR, but also support the company’s broader platform across high-unmet-need areas like ATTR amyloidosis, sickle cell disease, and immuno-oncology, bolstered by collaborations with Regeneron and Novartis.

Bear case

Intellia Therapeutics is exposed to significant fundamental risk because its CRISPR/Cas9 platform remains immature, with no CRISPR-based genome-editing therapeutics yet reaching clinical development and no approved product using genome editing. The company also depends on uncertain third-party patent rights and faces meaningful clinical execution risk, where setbacks in any program could undermine confidence in both the specific asset and the broader technology. Financially, it is likely to require additional equity financing to complete development of its drug candidates, increasing dilution risk, while changes in its Novartis and Regeneron collaborations could materially weaken shareholder value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.